SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
134,000
-2,300 (-1.69%)
At close: Dec 5, 2025

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 191.73B KRW in the quarter ending September 30, 2025, with 40.35% growth. This brings the company's revenue in the last twelve months to 675.41B, up 32.09% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.

Revenue (ttm)
675.41B
Revenue Growth
+32.09%
P/S Ratio
15.54
Revenue / Employee
2.75B
Employees
246
Market Cap
10.49T

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024547.60B192.70B54.30%
Dec 31, 2023354.89B108.71B44.16%
Dec 31, 2022246.18B-172.47B-41.20%
Dec 31, 2021418.64B392.65B1,510.23%
Dec 31, 202026.00B-97.85B-79.01%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 5,504.84B
Celltrion 3,895.99B
ALTEOGEN 202.18B
ABL Bio 88.44B
Yuhan 2,136.67B
LigaChem Biosciences 159.27B
Peptron 6.19B
HLB Co., Ltd. 80.73B
Revenue Rankings